Cytokine-mediated obesity stimulates intestinal cancer

Share This Post

A new study describes themechanistic relationship between thecytokine interleukin-1β(IL-1β) and obesity. WhenIL-1βlevels increase in obesity, theactivation ofIL-1receptor signaling leads to a large number of colon cancers. Kinds of ways. This study shows that obesity is related tothe systemic increase ofIL-1β,the  activation ofWntand the proliferation of mouse colon cells.

Joel Mason of Tufts University in Massachusetts and Tufts University School of Medicine and colleagues at Tufts University co-authored the article ” Interleukin- 1 Signaling Mediates Obesity-Promoted Increased Inflammatory Cytokines, Wnt Activation, and Small ” Proliferation of rat colonic epithelial cells ” article. “

The researchers set out to determine the role of IL-1β in regulating events leading to obesity-promoting colorectal cancer. They compared the role of IL-1β in mice fed a high-fat (obese) or low-fat (lean) diet. One of the changes they are found in obese mice having colon mucosa 30-80 % higher concentration of IL-l [beta] , the Wnt cascade significantly increased signal amplification and significantly proliferating crypts in the colon region.

“This study reveals the close link between obesity and inflammatory response, and reflects the extensive role of IL-1β , defining obesity as one of many inflammatory diseases, ” Department of Immunology , Washington University, Center for Innate Immunity and Immune Diseases. Michael Gale Jr. , editor-in-chief of Journal of Interferon & Cytokine Research, said.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy